Examining Data for Osimertinib in EGFR+ Lung Cancer

Heather A. Wakelee, MD, an associate professor at Stanford University School of Medicine, discusses the use of osimertinib (Tagrisso) as a frontline treatment option for patients withEGFR-positive lung cancer.

In this patient population, there are several first- and second-generation options, according to Wakelee. Third-generation osimertinib was approved by the FDA for this population, as well, with supportive data directly comparing different tyrosine kinase inhibitors in the frontline.